Breaking News Instant updates and real-time market news.

NVS

Novartis

$78.29

-0.16 (-0.20%)

17:07
10/09/16
10/09
17:07
10/09/16
17:07

Novartis reports data from ASCEND-3, ASCEND-5 trials of Zykadia

Novartis announced updated results from the Phase II ASCEND-3 trial, which demonstrated that anaplastic lymphoma kinase-positive non-small cell lung cancer patients taking Zykadia as their first ALK inhibitor had a median progression-free survival of 18.4 months, with a median follow-up time of 25.9 months. Further, in a sub-analysis of these data, patients who entered the study with brain metastases at baseline experienced an overall response rate of 63.3% and a disease control rate of 83.7%. These results were similar to those in patients without brain metastases, who demonstrated an ORR of 64.0% and DCR of 88.0%. At the time of analysis, the estimated 18-month overall survival rate was 73.4%. This population also demonstrated an ORR of 63.7% and median duration of response of 23.9 months. A decrease in tumor burden from baseline was shown in 94.7% patients. Results from the Phase III ASCEND-5 study were also presented for the first time. The ASCEND-5 study assessed median PFS in patients previously treated with crizotinib and one or two prior regimens of cytotoxic chemotherapy who then received either Zykadia or standard chemotherapy. Results demonstrated a statistically significant and clinically meaningful improvement in median PFS by BIRC for patients taking Zykadia versus chemotherapy. Median PFS by BIRC for Zykadia and chemotherapy were 5.4 months vs. 1.6 months, respectively.

NVS Novartis
$78.29

-0.16 (-0.20%)

08/31/16
LEER
08/31/16
NO CHANGE
Target $61
LEER
Outperform
Teva price target lowered to $61 from $66 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Teva (TEVA) to $61 from $66 on loss of Copaxone patent challenge as an upside catalyst. The analyst believes Teva's share price implies a generic entrant sometime in the second half of 2017 after losing an Inter Partes Review decision on two Copaxone 40mg anchor patents. In order to mitigate EPS downside in 2017-2018 and eliminate business uncertainty, Gerberry thinks the company should settle its Copaxone patent dispute with Novartis (NVS) and Momenta (MNTA), which he sees as "the most credible" generic threat. The analyst reiterates an Outperform rating on Teva's shares.
08/31/16
PIPR
08/31/16
NO CHANGE
PIPR
Piper's Schimmer unsure of impact from Novartis CAR-T shakeup
Piper Jaffray analyst Joshua Schimmer said he's struggling with the implications of the news that Novartis (NVS) is reportedly eliminating its Cell and Gene Therapy unit as a stand-alone entity, which is primarily focused on development of CAR-T and adoptive immunotherapies. On the one hand, removing a leading competitor is a positive for the rest of the field, Schimmer tells investors in a research note. On the other hand, the move by Novartis could signal "significant challenges" in the field, the analyst adds. Schimmer continues to prefer companies "with unique and differentiated approaches," namely Bellicum Pharmaceuticals (BLCM), Cellectis (CLLS), Lion Biotechnologies (LBIO), Amgen (AMGN), Celgene (CELG) and bluebird bio (BLUE). Juno Therapeutics (JUNO) and Kite Pharma (KITE) are down 6% and 5%, respectively, in midday trading.
09/02/16
LEER
09/02/16
NO CHANGE
LEER
Outperform
Teva third Copaxone patent invalidated as expected, says Leerink
Leerink analyst Jason Gerberry says Teva (TEVA) suffered a largely expected loss in its Copaxone 40mg patent battle, with the Patent Trial and Appeal Board, or PTAB, ruling a third patent invalid. The analyst believes the company will likely appeal the loss, along with PTAB rulings rendered last week that other Copaxone patents were invalid. Gerberry sees the bull case scenario of Teva securing patent exclusivity of the Copaxone 40mg as unlikely and says a settlement with Momenta (MNTA) and Novartis (NVS) is the most logical course of action to mitigate 2017-2018E EPS risk. He reiterates an Outperform rating on Teva's shares.
09/20/16
CHDN
09/20/16
INITIATION
Target $95
CHDN
Buy
Novartis initiated with a Buy at Chardan
Chardan initiated Novartis with a Buy and a $95 price target.

TODAY'S FREE FLY STORIES

WAB

Wabtec

$84.38

2.19 (2.66%)

20:53
04/25/17
04/25
20:53
04/25/17
20:53
Upgrade
Wabtec rating change at KeyBanc »

Wabtec upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 09

    May

  • 10

    May

CONN

Conn's

$14.80

0.3 (2.07%)

20:53
04/25/17
04/25
20:53
04/25/17
20:53
Upgrade
Conn's rating change at KeyBanc »

Conn's upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

SITE

SiteOne Landscape

$48.20

-0.4 (-0.82%)

20:43
04/25/17
04/25
20:43
04/25/17
20:43
Syndicate
SiteOne Landscape 10M share Secondary priced at $47.50 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

  • 26

    Apr

20:24
04/25/17
04/25
20:24
04/25/17
20:24
Periodicals
Trump tax plan to propose 10% tax on offshore profits, Bloomberg says »

President Donald Trump…

20:17
04/25/17
04/25
20:17
04/25/17
20:17
Periodicals
Trump administration drops support for border adjustment tax, NYT says »

The Trump administration…

DIS

Disney

$115.18

1.48 (1.30%)

20:11
04/25/17
04/25
20:11
04/25/17
20:11
Periodicals
ESPN layoffs could be harsher than expected, Sporting News says »

Layoffs at Disney's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PPG

PPG

$110.82

2.81 (2.60%)

, AKZOY

AkzoNobel

$30.00

0.27 (0.91%)

20:09
04/25/17
04/25
20:09
04/25/17
20:09
Periodicals
AkzoNobel says analysis of PPG offer to take time, Bloomberg reports »

AkzoNobel (AKZOY)…

PPG

PPG

$110.82

2.81 (2.60%)

AKZOY

AkzoNobel

$30.00

0.27 (0.91%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBGI

Sinclair Broadcast

$39.30

-0.15 (-0.38%)

, TRCO

Tribune Media

$36.55

-0.08 (-0.22%)

20:04
04/25/17
04/25
20:04
04/25/17
20:04
Hot Stocks
FCC chairman vows review of media ownership rules »

In a speech to the…

SBGI

Sinclair Broadcast

$39.30

-0.15 (-0.38%)

TRCO

Tribune Media

$36.55

-0.08 (-0.22%)

CBS

CBS

$66.41

0.46 (0.70%)

NXST

Nexstar

$68.90

0.3 (0.44%)

CMCSA

Comcast

$38.49

0.48 (1.26%)

CMCSK

Comcast

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Apr

  • 27

    Apr

  • 03

    May

  • 04

    May

  • 09

    May

  • 22

    May

  • 23

    May

  • 15

    Jun

FB

Facebook

$146.49

1.02 (0.70%)

19:57
04/25/17
04/25
19:57
04/25/17
19:57
Periodicals
Facebook tests news discovery methods, The Information says »

Facebook is testing new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

AVGO

Broadcom

$223.20

1.96 (0.89%)

, BRCD

Brocade

$12.58

0.01 (0.08%)

19:54
04/25/17
04/25
19:54
04/25/17
19:54
Periodicals
Broadcom, Brocade offer behavioral remedies to EU regulators, CTFN says »

Broadcom (AVGO) has…

AVGO

Broadcom

$223.20

1.96 (0.89%)

BRCD

Brocade

$12.58

0.01 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$146.49

1.02 (0.70%)

19:52
04/25/17
04/25
19:52
04/25/17
19:52
Hot Stocks
Facebook tests expanded 'Related Articles' feature »

Facebook announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

19:47
04/25/17
04/25
19:47
04/25/17
19:47
Periodicals
Trump administration considers additional trade actions, WSJ says »

The Trump administration…

PG

Procter & Gamble

$90.00

0.45 (0.50%)

, PEP

PepsiCo

$114.16

-0.16 (-0.14%)

19:25
04/25/17
04/25
19:25
04/25/17
19:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

PG

Procter & Gamble

$90.00

0.45 (0.50%)

PEP

PepsiCo

$114.16

-0.16 (-0.14%)

BA

Boeing

$183.51

1.45 (0.80%)

UTX

United Technologies

$116.87

0.55 (0.47%)

TMO

Thermo Fisher

$158.81

1.47 (0.93%)

GD

General Dynamics

$193.24

1.33 (0.69%)

ANTM

Anthem

$172.46

4.05 (2.40%)

NOC

Northrop Grumman

$248.13

-1.01 (-0.41%)

WM

Waste Management

$74.23

0.13 (0.18%)

IR

Ingersoll-Rand

$85.66

1.47 (1.75%)

DPS

Dr Pepper Snapple

$98.41

0.16 (0.16%)

HES

Hess Corp.

$48.64

0.98 (2.06%)

WYN

Wyndham

$92.22

0.43 (0.47%)

FLIR

FLIR Systems

$37.51

0.27 (0.73%)

NDAQ

Nasdaq

$70.53

0.08 (0.11%)

STT

State Street

$80.62

0.83 (1.04%)

APH

Amphenol

$72.18

0.25 (0.35%)

ROK

Rockwell Automation

$160.14

3.19 (2.03%)

BAX

Baxter

$53.21

-0.24 (-0.45%)

NSC

Norfolk Southern

$116.78

-0.27 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 26

    Apr

  • 02

    May

  • 03

    May

  • 06

    May

  • 11

    May

  • 17

    May

  • 18

    May

  • 31

    May

  • 06

    Jun

  • 15

    Jun

VZ

Verizon

$46.70

-0.35 (-0.74%)

19:20
04/25/17
04/25
19:20
04/25/17
19:20
Hot Stocks
Verizon introduces unlimited prepaid plan »

Verizon announced it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

NTB

Butterfield

$32.19

0.07 (0.22%)

19:12
04/25/17
04/25
19:12
04/25/17
19:12
Earnings
Butterfield reports Q1 core EPS 70c, consensus 64c »

Reports Q1 revenue $107M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

NBIX

Neurocrine

$53.62

1.84 (3.55%)

19:02
04/25/17
04/25
19:02
04/25/17
19:02
Hot Stocks
Neurocrine prices 30-count bottle of Ingrezza at $5,275 »

Neurocrine disclosed in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

MNOV

MediciNova

$5.57

0.14 (2.58%)

19:02
04/25/17
04/25
19:02
04/25/17
19:02
Hot Stocks
MediciNova: Survival rate from MN-166 open-label period 'significantly higher' »

MediciNova announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

FOX

21st Century Fox

$29.89

0.14 (0.47%)

, FOXA

21st Century Fox

$30.61

0.26 (0.86%)

18:50
04/25/17
04/25
18:50
04/25/17
18:50
Periodicals
8 more employees join Fox News lawsuit over race discrimination, FT says »

Eight current and former…

FOX

21st Century Fox

$29.89

0.14 (0.47%)

FOXA

21st Century Fox

$30.61

0.26 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    May

  • 15

    Jun

AMRI

Albany Molecular

$17.54

1.63 (10.25%)

, CG

Carlyle Group

$16.70

0.05 (0.30%)

18:44
04/25/17
04/25
18:44
04/25/17
18:44
Periodicals
Albany Molecular receives interest from Pamplona, Carlyle, Bloomberg says »

Albany Molecular (AMRI)…

AMRI

Albany Molecular

$17.54

1.63 (10.25%)

CG

Carlyle Group

$16.70

0.05 (0.30%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 06

    Jun

PTIE

Pain Therapeutics

$0.80

0.0285 (3.72%)

18:11
04/25/17
04/25
18:11
04/25/17
18:11
Hot Stocks
Pain Therapeutics sees completing additional Remoxy studies by year end »

"As previously…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

PTIE

Pain Therapeutics

$0.80

0.0285 (3.72%)

18:10
04/25/17
04/25
18:10
04/25/17
18:10
Hot Stocks
Breaking Hot Stocks news story on Pain Therapeutics »

Pain Therapeutics backs…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

PTIE

Pain Therapeutics

$0.80

0.0285 (3.72%)

18:09
04/25/17
04/25
18:09
04/25/17
18:09
Earnings
Pain Therapeutics reports Q1 EPS (6c), one estimate (6c) »

Reports Q1 net cash usage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

PHG

Philips

$34.69

0.14 (0.41%)

18:04
04/25/17
04/25
18:04
04/25/17
18:04
Hot Stocks
Philips Lighting repurchases 3.5M shares for roughly EUR101M »

Philips Lighting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PBF

PBF Energy

$22.56

0.26 (1.17%)

, WDR

Waddell & Reed

$17.92

-0.14 (-0.78%)

18:03
04/25/17
04/25
18:03
04/25/17
18:03
Hot Stocks
S&P announces changes to S&P MidCap 400, S&P SmallCap 600 indices »

S&P Dow Jones Indices…

PBF

PBF Energy

$22.56

0.26 (1.17%)

WDR

Waddell & Reed

$17.92

-0.14 (-0.78%)

SWC

Stillwater Mining

$17.99

0.09 (0.50%)

SBGL

Sibanye Gold

$8.14

-0.28 (-3.33%)

ARI

Apollo Commercial

$18.93

0.05 (0.26%)

ZLTQ

ZELTIQ

$56.49

-0.005 (-0.01%)

AGN

Allergan

$238.22

1.24 (0.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 02

    May

  • 03

    May

  • 04

    May

  • 04

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 11

    May

  • 31

    May

FRO

Frontline

$6.73

0.06 (0.90%)

, DHT

DHT Holdings

$4.67

0.04 (0.86%)

18:02
04/25/17
04/25
18:02
04/25/17
18:02
Hot Stocks
Frontline says makes new offer to DHT Holdings »

Frontline (FRO) issued…

FRO

Frontline

$6.73

0.06 (0.90%)

DHT

DHT Holdings

$4.67

0.04 (0.86%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.